SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

08 Nov 2023 Evaluate
The September 2023 quarter revenue stood at Rs. 4097.09 millions, up 15.29% as compared to Rs. 3553.69 millions during the corresponding quarter last year.A meek growth of 2.27% was reported for the quarter ended September 2023 to Rs. 1178.07  millions from Rs. 1151.97 millions.OP of the company witnessed a marginal growth to 1514.66 millions from 1472.01 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 4097.09 3553.69 15.29 8209.96 6841.29 20.01 13307.25 12157.30 9.46
Other Income 69.75 61.53 13.36 110.01 95.25 15.50 172.64 289.89 -40.45
PBIDT 1514.66 1472.01 2.90 3109.93 2767.60 12.37 5223.78 5129.84 1.83
Interest 65.45 74.86 -12.57 133.87 147.12 -9.01 208.10 29.91 595.75
PBDT 1449.21 1397.15 3.73 2976.06 2620.48 13.57 5015.68 5099.93 -1.65
Depreciation 250.01 159.04 57.20 451.64 308.76 46.28 646.57 514.55 25.66
PBT 1199.20 1238.11 -3.14 2524.42 2311.72 9.20 4369.11 4585.38 -4.72
TAX 21.13 86.14 -75.47 238.93 203.84 17.21 389.03 413.46 -5.91
Deferred Tax -197.26 -122.56 60.95 -196.82 -198.80 -1.00 -375.93 -388.26 -3.18
PAT 1178.07 1151.97 2.27 2285.49 2107.88 8.43 3980.08 4171.92 -4.60
Equity 136.02 135.99 0.02 136.02 135.99 0.02 135.99 135.93 0.04
PBIDTM(%) 36.97 41.42 -10.75 37.88 40.45 -6.36 39.26 42.20 -6.97

Eris Lifesciences Share Price

1446.50 -18.90 (-1.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×